Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by StockNews.com

Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

Separately, HC Wainwright reissued a “neutral” rating on shares of Aclaris Therapeutics in a research note on Tuesday, September 17th.

Aclaris Therapeutics Price Performance

NASDAQ:ACRS opened at $2.05 on Friday. Aclaris Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.72. The firm has a 50-day moving average of $1.49 and a two-hundred day moving average of $1.30. The stock has a market cap of $146.43 million, a P/E ratio of -3.94 and a beta of 0.10.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The business had revenue of $4.35 million for the quarter, compared to analyst estimates of $8.31 million. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. As a group, equities analysts expect that Aclaris Therapeutics will post -0.65 earnings per share for the current year.

Hedge Funds Weigh In On Aclaris Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in Aclaris Therapeutics in the 1st quarter worth approximately $39,000. SG Americas Securities LLC increased its position in shares of Aclaris Therapeutics by 69.5% during the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 13,461 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Aclaris Therapeutics by 5,265.1% in the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 61,602 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Aclaris Therapeutics in the second quarter worth $119,000. Finally, Assenagon Asset Management S.A. bought a new stake in Aclaris Therapeutics in the 3rd quarter valued at $214,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.